We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 02, 2020

Comparative Treatment Patterns and Outcomes of Fulvestrant vs Everolimus + Exemestane for Postmenopausal MBC Resistant to AI in Real-World Experience

Therapeutics and Clinical Risk Management


Additional Info

Disclosure statements are available on the authors' profiles:

Therapeutics and Clinical Risk Management
Comparative Treatment Patterns and Outcomes of Fulvestrant Versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
Ther Clin Risk Manag 2020 Aug 01;16(2020)607-615, Y Li, Y Xie, C Gong, Y Zhao, J Zhang, S Zhang, L Wang, S Chen, X Hu, B Wang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading